Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 21
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Verrica Pharmaceuticals Inc
VRCA
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$3.63
0.16
4.61%
Ult. Agg.: Oct 21, 4:54 PM
$3.50
0.03
0.86%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Verrica Pharmaceuticals Financials
Verrica Pharmaceuticals (VRCA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.38) by 26.32 percent. This is a 292 percent decrease over earnings of $0.25 per
Benzinga Newsdesk
PRO
Verrica Pharmaceuticals Q1 Adj. EPS $(0.41) Misses $(0.38) Estimate, Sales $5.023M Beat $4.520M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.89 percent. This is a 53.41 percent increase over losses of $(0.88) per
Benzinga Newsdesk
Earnings Scheduled For May 12, 2026
Benzinga Insights
PRO
Verrica Pharmaceuticals Q4 Adj. EPS $(0.51) Beats $(0.79) Estimate, Sales $5.092M Beat $4.525M Estimate
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.79) by 35.77 percent. This is a 71.67 percent increase over losses of $(1.80) per
Benzinga Newsdesk
Earnings Scheduled For March 11, 2026
Benzinga Insights
Earnings Outlook For Verrica Pharmaceuticals
Benzinga Insights
